

Peter M Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10608633/publications.pdf>

Version: 2024-02-01

26
papers

1,463
citations

394421

19
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

2734
citing authors

#	ARTICLE	IF	CITATIONS
1	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 282-298.	27.6	312
2	Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab. <i>Clinical Cancer Research</i> , 2008, 14, 7884-7895.	7.0	116
3	Pharmacogenomic Identification of Novel Determinants of Response to Chemotherapy in Colon Cancer. <i>Cancer Research</i> , 2006, 66, 2765-2777.	0.9	99
4	Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence. <i>Clinical Cancer Research</i> , 2011, 17, 6934-6943.	7.0	91
5	DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. <i>BMC Medical Genomics</i> , 2009, 2, 67.	1.5	85
6	The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models. <i>Cancer Research</i> , 2011, 71, 3635-3648.	0.9	78
7	Molecular Markers in the Treatment of Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> 10.784314 rgBT /Overlo 2.0 77	2.0	77
8	A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates. <i>Nucleic Acids Research</i> , 2011, 39, e112-e112.	14.5	75
9	Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 463-473.	5.1	68
10	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 979-988.	2.3	52
11	Novel opportunities for thymidylate metabolism as a therapeutic target. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3029-3037.	4.1	51
12	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. <i>Nucleic Acids Research</i> , 2009, 37, 78-95.	14.5	50
13	The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 128-137.	4.1	45
14	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase—Targeted Therapies in Non—Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 616-628.	4.1	44
15	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5591-5602.	7.0	43
16	The dual EGFR/HER2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. <i>International Journal of Cancer</i> , 2009, 125, 2957-2969.	5.1	37
17	Calbindin 2 (CALB2) Regulates 5-Fluorouracil Sensitivity in Colorectal Cancer by Modulating the Intrinsic Apoptotic Pathway. <i>PLoS ONE</i> , 2011, 6, e20276.	2.5	33
18	Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. <i>International Journal of Cancer</i> , 2011, 129, 1096-1104.	5.1	28

#	ARTICLE	IF	CITATIONS
19	Assessing the in vivo efficacy of biologic antiangiogenic therapies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1-12.	2.3	22
20	Sustained inhibition of deacetylases is required for the antitumor activity of the histone deacetylase inhibitors panobinostat and vorinostat in models of colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 845-857.	2.6	18
21	Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 38.	5.2	12
22	Predictive and prognostic markers in colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2007, 1, 237-46.	0.7	9
23	Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, S16-S27.	2.3	7
24	A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2251-2258.	4.1	6
25	Exploring Alternative Individualized Treatment Strategies in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 7, S28-S36.	2.3	5
26	Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 183-192.	0.5	0